Compare Crispr Therapeutics AG (CRSP) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Marriott International Inc — how do they compare? Crispr Therapeutics AG trades at $53.71 (market cap $5.23B), while Marriott International Inc trades at $354.75 (market cap $91.14B). The key difference: Marriott International Inc is far larger — about 17.4× Crispr Therapeutics AG's market cap, and Marriott International Inc pays a 0.84% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | MAR | |
|---|---|---|
Market Cap | $5.23B | $91.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $402.54 |
52-Week Low | $44.34 | $259.04 |
Enterprise Value | $3.65B | $108.45B |
Dividend Yield | — | 0.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Marriott International (MAR) trades at $348.44, down 1.55% on the day, with a bearish technical signal and mixed earnings performance. The company reported Q2 2026 EPS of $3.19, beating estimates, but revenue growth faces headwinds. Key risks include high debt levels and valuation concerns, while analyst consensus remains positive with a $387.31 price target.
Outlook: MAR's fee-based model and loyalty program drive growth, but elevated P/E of 36.18 and rising debt-to-asset ratio warrant caution. Upside hinges on sustained RevPAR gains and effective cost management amid global economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
